Advanced of HER-2/neu epitope anti-tumor vaccine

doi:10.12092/j.issn.1009-2501.2019.09.013

Abstract

Abstract:

Overexpression of HER-2/neu oncogene is a frequent molecular event in multiple human cancer, including breast cancer (20%-40%), colorectal cancer (54%-100%), ovarian cancer (25%). Therefore, HER-2/neu protein is one of the candidate target antigens for cancer, and has been proved to have the potential to develop anti-breast cancer vaccines. At present, a series of studies have been carried out on different types of HER-2 vaccines, including whole-cell vaccines, full-sequence protein vaccines, peptide vaccines and DC-induced vaccines, and some progress has been made. A baidu Scholar, PubMed, Springer and ScienceDirect database search was performed to review the advanced of the preparation technology and the mechanism of antineoplastic activity of tumor vaccine based on HER-2/neu antigen. As the conclusions shown in the present paper, CD4+T and CD8+T were activated successfully and the anti-tumor specific immune response was induced by the antigen presenting cells (APCs) presented with the HER-2/neu tumor vaccine antigenic epitope. The immunological and anti-tumor activity would be improved by the change of vaccine design process, such as the reform of composition structure, fusion expression with immune-boosting short peptides and dendritic cell induced. The defect of drug resistance and repeated administration accompanied by HER-2 monoclonal antibody treatment and the serious toxicity of traditional chemotherapy drugs treatment could be reduced by HER-2 anti-tumor vaccine treatment with the stable anti-tumor activity in the clinic trail, which would provide a new perspective of tumor treatment.

Key words: HER-2/neu, tumor vaccine, dendritic cell, immune activity

CLC Number:

R730.51

LIN Zhong, XIE Qunli, LI Shengying, JIN Hui, XU Fenfen, XIE Liyun, JIANG Zhengli. Advanced of HER-2/neu epitope anti-tumor vaccine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1046-1052.

References

［1］Couzin-Frankel J. Breakthrough of the year "Cancer Immunotherapy"［J］. Science, 2013, 342(6165): 1432-1433.
［2］Garber K. Driving T-cell immunotherapy to solid tumors［J］. Nat Biotechnol, 2018, 36(3): 215-219.
［3］Schaller TH, Sampson JH. Advances and challenges: dendritic cell vaccination strategies for glioblastoma［J］. Expert Rev Vaccines, 2017, 16(1): 27-36.
［4］王艳梅, 陈坤, 曲春枫. 肿瘤疫苗的研究进展［J］. 国际免疫学杂志, 2018, 41(6): 683-689.
［5］Shin SH, Park SS, Ju EJ, et al. Establishment of a patient-derived xenograft for development of personalized HER-2-targeting therapy in gastric cancer［J］. Anticancer Res, 2018, 38(1): 287-293.
［6］Shang AQ, Wu J, Bi F, et al. Relationship between HER-2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer［J］. Cancer Biol Ther, 2017, 18(5): 314-322.
［7］Subbarayan K, Leisz S, Wickenhauser C, et al. Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells［J］. Oncoimmunology, 2018, 7(4): e1373233.
［8］Kimball A, Patil S, Koczwara B, et al. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients［J］. Int J Cardiol, 2018, 261159-261161.
［9］Liu W, Zhai X, Wang W, et al. Aldehyde dehydrogenase 2 activation ameliorates cyclophosphamide-induced acute cardiotoxicity via detoxification of toxic aldehydes and suppression of cardiac cell death［J］. J Mol Cell Cardiol, 2018, 121134-121144.
［10］Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER-2(+) breast cancer: Current landscape and future perspectives［J］. Cancer Treat Rev, 2017, 61107-61115.
［11］赵丽丽, 姜北海, 寿成超. HER-2/neu肿瘤疫苗的研究进展［J］. 中国肿瘤生物治疗杂志, 2010, 17(2): 221-226.
［12］Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER-2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet Oncol, 2018, 19(1): 87-100.
［13］Adamczyk A, Grela-Wojewoda A, Domagala-Haduch M, et al. Proteins involved in HER-2 signalling pathway, their relations and influence on metastasis-free survival in HER-2-positive breast cancer patients treated with trastuzumab in adjuvant setting［J］. J Cancer, 2017, 8(1): 131-139.
［14］He Y, Rozeboom L, Rivard CJ, et al. MHC class II expression in lung cancer［J］. Lung Cancer, 2017, 11275-11280.
［15］Smahel M. PD-1/PD-L1 blockade therapy for tumors with downregulated MHC class I expression［J］. Int J Mol Sci, 2017, 18(6), doi: 10.3390/ijms18061331.
［16］Lee JH, Son YH, Kwon YW, et al. Anticancer effects of a Korean herbal medicine formula (H9) via AMPK and HER-2-PI3K/Akt signaling in breast cancer cells［J］. Phytother Res, 2017, 31(11): 1765-1775.
［17］Pupa SM, Invernizzi AM, Forti S, et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination［J］. Gene Therapy, 2001, 8(1): 75-79.
［18］Smorlesi A, Papalini F, Amici A, et al. Evaluation of different plasmid DNA delivery systems for immunization against HER-2/neu in a transgenic murine model of mammary carcinoma［J］. Vaccine, 2006, 24(11): 1766-1775.
［19］Falk K, Rtzschke O, Stevanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules［J］. Nature, 1991, 351(6324): 290-296.
［20］陈龙冠, 宋燕, 许元生, 等. 针对HER-2的多肽疫苗CKL9与YL20的抗肿瘤活性研究［J］. 中国药理学通报，2017, 33(7): 997-1002.
［21］Amin A, Benavides LC, Holmes JP, et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER-2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02［J］. Can Immunol Immunothera, 2008, 57(12): 1817-1825.
［22］Khoo S, Storrer C, Harris K, et al. Early results of a phase I clinical trial of an Ii-Key/HER-2/neu MHC Class II peptide-based vaccine in breast cancer patients［J］. J Am Col Surg, 2006, 203(3): S81.
［23］Gates JD, Carmichael MG, Benavides LC, et al. Longterm followup assessment of a HER-2/neu peptide (E75) vaccine for prevention of recurrence in high［J］. J Am Col Surg, 2009, 208(2): 193-201.
［24］Patil R, Clifton GT, Holmes JP, et al. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER-2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial［J］. J Am Col Surg, 2010, 210(2): 140-147.
［25］Disis ML, Gooley TA, Kristine R, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines［J］. J Clin Oncol Off J Am Soc Clin Oncol, 2002, 20(11): 2624-2632.
［26］龙敏, 董柯, 王希, 等. HER-2/ECD-sf162/TM嵌合VLPs的制备及抗肿瘤免疫效果研究［J］. 现代肿瘤医学，2016, 24(21): 3355-3359.
［27］ML D, DR W, TA G, et al. Concurrent trastuzumab and HER-2/neu-specific vaccination in patients with metastatic breast cancer［J］. J Clin Oncol, 2009, 27(28): 4685-4692.
［28］Norell H, Poschke I, Charo J, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial［J］. J Transl Med, 2010, 8(6): 53.
［29］Aoki M, Ueda S, Nishikawa H, et al. Antibody responses against NY-ESO-1 and HER-2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER-2 with OK-432［J］. Vaccine, 2009, 27(49): 6854-6861.
［30］Danko JR, Kochel T, Teneza-Mora N, et al. Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial［J］. Am J Trop Med Hyg, 2018, 98(3): 849-856.
［31］Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved toll-like receptor agonists for cancer therapy［J］. Oncoimmunol, 2012, 1(6): 894-907.
［32］Sheida S, Ali B, Seyed Amir J, et al. P5 HER-2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer［J］. Cancer Letters, 2014, 355(1): 54-60.
［33］Jang JE, Hajdu CH, Liot C, et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer［J］. Cell Rep, 2017, 20(3): 558-571.
［34］Shang N, Figini M, Shangguan J, et al. Dendritic cells based immunotherapy［J］. Am J Cancer Res, 2017, 7(10): 2091-2102.
［35］Rosenthal KS, Stone S, Koski G, et al. LEAPS vaccine incorporating HER-2/neu epitope elicits protection that prevents and limits tumor growth and spread of breast cancer in a mouse model［J］. J Immunol Res, 2017, 20173613505.
［36］冯喆, 张剑, 李文桦, 等. 术前应用HER2特异性树突状细胞疫苗治疗导管原位癌患者的安全性和有效性评估［J］. 循证医学, 2018, 18(3): 137-139.
［37］戴辉腾, 田浤, 黄捷, 等. 含对硝基苯丙氨酸的B淋巴细胞刺激因子疫苗对狼疮肾炎模型小鼠的保护作用［J］. 中国药科大学学报, 2017, 48(4): 483-489.
［38］蔡棣, 田浤, 姚文兵. 含有L-对硝基苯丙氨酸的BAFF改构体的分子动力学模拟与分析［J］. 中国药科大学学报, 2017, 48(2): 227-232.

[1]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[2]	HU Yuping, ZHOU Haiyun, HUANG Qiaoling, YAO Yimin. Effect of paeonol on the expression of cytokines production and maturation of DCs co-stimulated by FSL-1 and IL-4 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 14-19.
[3]	CHEN Ye, HE Shoudi, HU Zhili, FENG Bin. TIM4 expression of dendritic cells and inflammation effects in OVA-induced asthma model treated with lentinan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 998-1002.
[4]	LIU Hong-hong, CHEN Xiao-hua, ZHOU Li-qin, LIU Xue-ni, YU Yong-sheng, ZANG Guo-qing, TANG Zheng-hao. Transmission functions of fusion protein CTP-HBcAg18-27-Tapasin in the cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 25-29.
[5]	WANG Qiong, ZHU Xue-jun. Experimental study on astragalus polysaccharides promoting the human dendritic cells maturation in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1348-1352.
[6]	HE Xiu-juan, ZHANG Han, LI Dong-mei, QIU Yong, LONG Jun, AN Yun-qing, HU Yong-xiu. Effects of sirolimos on the expression of CD₈₆, I-A^b and TLR4 on mice dendritic cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1133-1138.
[7]	WU Xiang-ling, HE Xiao-kui, LI Bo, HU Yong-xiu. Effects of dexamethasone on toll-like receptor 4 mediated signaling pathways in mice dendritic cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 1023-1027.
[8]	HE Xiao-kui, HU Yong-xiu. Mechanisms of Dexamethasone inducing generation of tolerogenic dendritic cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 113-116.